Iguratimod
Iguratimod is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target macrophage migration inhibitory factor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
22 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | 1 | 7 | 1 | 9 |
| Immunoglobulin g4-related disease | D000077733 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lupus nephritis | D008181 | EFO_0005761 | — | 1 | — | — | 1 | 2 | |
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | 2 | — | — | — | 2 |
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney transplantation | D016030 | — | — | — | — | 1 | 1 | ||
| Diffuse scleroderma | D045743 | EFO_0000404 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | IGURATIMOD |
| INN | iguratimod |
| Description | Iguratimod is an organic molecular entity. |
| Classification | Small molecule |
| Drug class | immunomodulators |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 123663-49-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2107455 |
| ChEBI ID | — |
| PubChem CID | 124246 |
| DrugBank | DB12233 |
| UNII ID | 4IHY34Y2NV (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
MIF
MIF
Organism
Homo sapiens
Gene name
MIF
Gene synonyms
GLIF, MMIF
NCBI Gene ID
Protein name
macrophage migration inhibitory factor
Protein synonyms
epididymis secretory sperm binding protein, GIF, Glycosylation-inhibiting factor, L-dopachrome isomerase, L-dopachrome tautomerase, macrophage migration inhibitory factor (glycosylation-inhibiting factor), Phenylpyruvate tautomerase
Uniprot ID
Mouse ortholog
Mif (17319)
macrophage migration inhibitory factor (P34884)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 386 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
198 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more